Effectiveness, and safety of orally-administered immunotherapy for food allergy

systematic review and meta-analysis

Ulugbek Nurmatov, Graham Devereux, Allison Worth, Laura Healy, Aziz Sheikh

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The aim of using oral and sublingual immunotherapy with food allergies is to enable the safe consumption of foods containing these allergens in patients with food allergies. In the present study, a systematic review of intervention studies was undertaken; this involved the searching of eleven international databases for controlled clinical trials. We identified 1152 potentially relevant papers, from which we selected twenty-two reports of twenty-one eligible trials (i.e. eighteen randomised controlled trials and three controlled clinical trials). The meta-analysis revealed a substantially lower risk of reactions to the relevant food allergen in those receiving orally administered immunotherapy (risk ratios (RR) 0·21, 95 % CI 0·12, 0·38). The meta-analysis of immunological data demonstrated that skin prick test responses to the relevant food allergen significantly decreased with immunotherapy (mean difference − 2·96 mm, 95 % CI − 4·48, − 1·45), while allergen-specific IgG4 levels increased by an average of 19·9 (95 % CI 17·1, 22·6) μg/ml. Sensitivity analyses excluding studies at the highest risk of bias and subgroup analyses in relation to specific food allergens and treatment approaches generated comparable summary estimates of effectiveness and immunological changes. Pooling of the safety data revealed an increased risk of local (i.e. minor oropharyngeal/gastrointestinal) adverse reactions with immunotherapy (RR 1·47, 95 % CI 1·11, 1·95); there was a non-significant increased average risk of systemic adverse reactions with immunotherapy (RR 1·08, 95 % CI 0·97, 1·19). There is strong evidence that orally administered immunotherapy can induce immunomodulatory changes and thereby promote desensitisation to a range of foods. However, given the paucity of evidence on longer-term safety, effectiveness and cost-effectiveness, orally administered immunotherapy should not be used outside experimental conditions presently.
Original languageEnglish
Pages (from-to)12-22
Number of pages11
JournalBritish Journal of Nutrition
Volume111
Issue number1
Early online date15 Aug 2013
DOIs
Publication statusPublished - Jan 2014

Fingerprint

Food Hypersensitivity
Immunotherapy
Meta-Analysis
Allergens
Safety
Food
Odds Ratio
Controlled Clinical Trials
Sublingual Immunotherapy
Skin Tests
Cost-Benefit Analysis
Randomized Controlled Trials
Immunoglobulin G
Databases

Keywords

  • food allergies
  • oral immunotherapy
  • sublingual immunotherapy
  • systematic reviews
  • meta-analyses

Cite this

Effectiveness, and safety of orally-administered immunotherapy for food allergy : systematic review and meta-analysis. / Nurmatov, Ulugbek; Devereux, Graham; Worth, Allison; Healy, Laura ; Sheikh, Aziz.

In: British Journal of Nutrition, Vol. 111, No. 1, 01.2014, p. 12-22.

Research output: Contribution to journalArticle

Nurmatov, Ulugbek ; Devereux, Graham ; Worth, Allison ; Healy, Laura ; Sheikh, Aziz. / Effectiveness, and safety of orally-administered immunotherapy for food allergy : systematic review and meta-analysis. In: British Journal of Nutrition. 2014 ; Vol. 111, No. 1. pp. 12-22.
@article{cb9b2a1c0b454adc9299339dd1531657,
title = "Effectiveness, and safety of orally-administered immunotherapy for food allergy: systematic review and meta-analysis",
abstract = "The aim of using oral and sublingual immunotherapy with food allergies is to enable the safe consumption of foods containing these allergens in patients with food allergies. In the present study, a systematic review of intervention studies was undertaken; this involved the searching of eleven international databases for controlled clinical trials. We identified 1152 potentially relevant papers, from which we selected twenty-two reports of twenty-one eligible trials (i.e. eighteen randomised controlled trials and three controlled clinical trials). The meta-analysis revealed a substantially lower risk of reactions to the relevant food allergen in those receiving orally administered immunotherapy (risk ratios (RR) 0·21, 95 {\%} CI 0·12, 0·38). The meta-analysis of immunological data demonstrated that skin prick test responses to the relevant food allergen significantly decreased with immunotherapy (mean difference − 2·96 mm, 95 {\%} CI − 4·48, − 1·45), while allergen-specific IgG4 levels increased by an average of 19·9 (95 {\%} CI 17·1, 22·6) μg/ml. Sensitivity analyses excluding studies at the highest risk of bias and subgroup analyses in relation to specific food allergens and treatment approaches generated comparable summary estimates of effectiveness and immunological changes. Pooling of the safety data revealed an increased risk of local (i.e. minor oropharyngeal/gastrointestinal) adverse reactions with immunotherapy (RR 1·47, 95 {\%} CI 1·11, 1·95); there was a non-significant increased average risk of systemic adverse reactions with immunotherapy (RR 1·08, 95 {\%} CI 0·97, 1·19). There is strong evidence that orally administered immunotherapy can induce immunomodulatory changes and thereby promote desensitisation to a range of foods. However, given the paucity of evidence on longer-term safety, effectiveness and cost-effectiveness, orally administered immunotherapy should not be used outside experimental conditions presently.",
keywords = "food allergies, oral immunotherapy, sublingual immunotherapy, systematic reviews, meta-analyses",
author = "Ulugbek Nurmatov and Graham Devereux and Allison Worth and Laura Healy and Aziz Sheikh",
year = "2014",
month = "1",
doi = "10.1017/S0007114513002353",
language = "English",
volume = "111",
pages = "12--22",
journal = "British Journal of Nutrition",
issn = "0007-1145",
publisher = "Cambridge Univ. Press.",
number = "1",

}

TY - JOUR

T1 - Effectiveness, and safety of orally-administered immunotherapy for food allergy

T2 - systematic review and meta-analysis

AU - Nurmatov, Ulugbek

AU - Devereux, Graham

AU - Worth, Allison

AU - Healy, Laura

AU - Sheikh, Aziz

PY - 2014/1

Y1 - 2014/1

N2 - The aim of using oral and sublingual immunotherapy with food allergies is to enable the safe consumption of foods containing these allergens in patients with food allergies. In the present study, a systematic review of intervention studies was undertaken; this involved the searching of eleven international databases for controlled clinical trials. We identified 1152 potentially relevant papers, from which we selected twenty-two reports of twenty-one eligible trials (i.e. eighteen randomised controlled trials and three controlled clinical trials). The meta-analysis revealed a substantially lower risk of reactions to the relevant food allergen in those receiving orally administered immunotherapy (risk ratios (RR) 0·21, 95 % CI 0·12, 0·38). The meta-analysis of immunological data demonstrated that skin prick test responses to the relevant food allergen significantly decreased with immunotherapy (mean difference − 2·96 mm, 95 % CI − 4·48, − 1·45), while allergen-specific IgG4 levels increased by an average of 19·9 (95 % CI 17·1, 22·6) μg/ml. Sensitivity analyses excluding studies at the highest risk of bias and subgroup analyses in relation to specific food allergens and treatment approaches generated comparable summary estimates of effectiveness and immunological changes. Pooling of the safety data revealed an increased risk of local (i.e. minor oropharyngeal/gastrointestinal) adverse reactions with immunotherapy (RR 1·47, 95 % CI 1·11, 1·95); there was a non-significant increased average risk of systemic adverse reactions with immunotherapy (RR 1·08, 95 % CI 0·97, 1·19). There is strong evidence that orally administered immunotherapy can induce immunomodulatory changes and thereby promote desensitisation to a range of foods. However, given the paucity of evidence on longer-term safety, effectiveness and cost-effectiveness, orally administered immunotherapy should not be used outside experimental conditions presently.

AB - The aim of using oral and sublingual immunotherapy with food allergies is to enable the safe consumption of foods containing these allergens in patients with food allergies. In the present study, a systematic review of intervention studies was undertaken; this involved the searching of eleven international databases for controlled clinical trials. We identified 1152 potentially relevant papers, from which we selected twenty-two reports of twenty-one eligible trials (i.e. eighteen randomised controlled trials and three controlled clinical trials). The meta-analysis revealed a substantially lower risk of reactions to the relevant food allergen in those receiving orally administered immunotherapy (risk ratios (RR) 0·21, 95 % CI 0·12, 0·38). The meta-analysis of immunological data demonstrated that skin prick test responses to the relevant food allergen significantly decreased with immunotherapy (mean difference − 2·96 mm, 95 % CI − 4·48, − 1·45), while allergen-specific IgG4 levels increased by an average of 19·9 (95 % CI 17·1, 22·6) μg/ml. Sensitivity analyses excluding studies at the highest risk of bias and subgroup analyses in relation to specific food allergens and treatment approaches generated comparable summary estimates of effectiveness and immunological changes. Pooling of the safety data revealed an increased risk of local (i.e. minor oropharyngeal/gastrointestinal) adverse reactions with immunotherapy (RR 1·47, 95 % CI 1·11, 1·95); there was a non-significant increased average risk of systemic adverse reactions with immunotherapy (RR 1·08, 95 % CI 0·97, 1·19). There is strong evidence that orally administered immunotherapy can induce immunomodulatory changes and thereby promote desensitisation to a range of foods. However, given the paucity of evidence on longer-term safety, effectiveness and cost-effectiveness, orally administered immunotherapy should not be used outside experimental conditions presently.

KW - food allergies

KW - oral immunotherapy

KW - sublingual immunotherapy

KW - systematic reviews

KW - meta-analyses

U2 - 10.1017/S0007114513002353

DO - 10.1017/S0007114513002353

M3 - Article

VL - 111

SP - 12

EP - 22

JO - British Journal of Nutrition

JF - British Journal of Nutrition

SN - 0007-1145

IS - 1

ER -